chris van ingen   facebook facebook？english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   bloomberg bloombergcom businessweekcom bloomberg tv premium professional products bloomberg anywhere bloomberg tradebook industry products bloomberg briefs bloomberg government bloomberg law bloomberg bna bloomberg new energy finance bloomberg sports enterprise products compliance solutions data solutions technology solutions trading solutions consumer products bloombergblack this site uses cookies by continuing to browse the site you are agreeing to our use of cookies x bloomberg our company professional anywhere home quick news opinion market data personal finance tech politics sustainability luxury tv video radio   http error  file not found the page you requested cannot be found the page youre looking for might have been moved its name might have changed or it might be temporarily unavailable what to do try search enter your subjects keywords into the search box at the top of the page try our sitemap all of bloombergcom laid out by subject and function bloomberg homepage more mobile apps businessweekcom bloomberg visual data insights series bloomberg blog top headlines most popular exclusive law entrepreneurs leaders muse arts  culture economy environment science sports markets magazine pursuits magazine regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe more regions markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance more markets industries energy technology real estate finance health care transportation insurance retail media more industries editorials commentary echoes the ticker world view sponsored by stocks stock futures world indexes gainers  losers regional indexes earnings currencies world currencies foreign exchange rates forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries bond indexes corporate bonds consumer rates etfs mutual funds economic calendar watchlist european debt crisis overview saving  investing wealth real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery insurance  health portfolio impact calculators watchlist portfolio tracker overview social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos overview elections white house congress state  local political capital videos live blogs overview energy corporate sustainability policy natural resources health  population slideshows videos blog the grid muse arts  culture billionaires living property travel well spent loot blog pursuits magazine videos live tv channel finder personalities ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers more shows must see latest most watched interviews playlist live radio shows schedule personalities podcasts first word surveillance taking stock more podcasts bloomberg radio live tv bloombergcom news opinion markets personal finance tech sustainability luxury tv video radio archives about our company careers advertising licensing press room trademarks terms of service privacy policy support and contact customer support contacts feedback help sitemap stay connected twitter facebook linked in google stumbleupon bloomberg terminal professional subscriber login faq related bloomberg sites bloomberg businessweek bloomberg institute ブ ルームバーグ  bloomberg markets magazine open bloomberg bloomberg link bloomberg blog bloomberg books bloomberg premium services bloomberg briefs bloomberg government bloomberg law bloomberg bna bloomberg new energy finance bloomberg sports bloombergblack mobile apps bloomberg bloomberg radio bloomberg tv bloomberg businessweek bloomberg markets bloomberg anywhere  bloomberg lp all rights reserved jobs by indeed rate this page made in nyc ad choices chris van ingen  lifeonics chris van ingenindependent director since  chris van ingen has been an advisor to various life sciences analytical product and informatics companies he currently serves on the board of directors of the bruker corporation promega corporation and trinean nv from  to  he also served on the board of directors of alpha innotech accelrys and proteinsimple from  to  he was president of agilent technologies’ life sciences and chemical analysis group from  to  he was vice president of sales and marketing at hewlett packard’s chemical analysis group and from  to  held several senior management positions at hewlett packard’s avondale division and netherlands country operation  chris is based in the bay area and holds a bs degree in analytical chemistry and an executive mba life sciences  critical evaluation  realistic  marketing  profile detailscategoriesboardmembers ian sandersandrew punnett pages distributors home privacy policy purchase a smod smod software download smod news about us contact us contact informationlifeonics ltdecentre gate  oaklands roadmassey universityaucklandphone    email infolifeonicscom  facebook facebook   ？ facebook ？？换一个或播放语音验证信息框字：？，。提交english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   news article  proteinsimple proteinsimple appoints joe keegan and chris van ingen to its board of directors back to news santa clara ca march    proteinsimple announced today the appointments of two independent members of the companys board of directors mr chris van ingen and dr joe keegan chris and joe are two of the most respected leaders in the life science tool industry commented tim harkness ceo of proteinsimple they bring tremendous depth of experience and knowledge about building successful life science technology companies we are privileged to have them join our team about joe keegan dr keegan brings more than  years of experience managing high growth life science businesses most recently he served as the ceo of fortebio where he transformed the company from a startup in  to a fast growing leader in labelfree protein analysis fortebio was acquired in  by pall corporation previously dr keegan was the ceo of molecular devices mdc during his year tenure at mdc dr keegan grew the companys revenue from  million to  million at which point the company was sold to mds inc for  million prior to mdc dr keegan served as president of worldwide tissue culture of becton dickinson and vice president of microscope and scientific instruments division of leica he currently serves on the board of directors of alda as immediate past chairman advanced cell diagnostics labcyte corporation as chairman response biomedical corp seahorse bioscience inc stereotaxis inc and the san francisco opera dr keegan holds a ba in chemistry from boston university and a phd in physical chemistry from stanford university about chris van ingen mr van ingen has over two decades of senior management leadership experience and has served as an advisor to many life science companies most recently as president of agilent technologies bioanalytical measurement business he oversaw the growth of that business from  billion to over  billion in annual revenues in less than  years mr van ingen currently serves on the board of directors of bruker est inc accelrys inc as chairman and promega corporation in addition mr van ingen serves as a strategic consultant to several companies in the life sciences and chemical analysis instrumentation industry he previously served as a director of alpha innotech corporation and symyx technologies inc until its merger with accelrys in july  mr van ingen holds a bs degree in analytical chemistry about proteinsimple our goal is simply to help researchers gain a better understanding of proteins and their role in disease we develop and commercialize proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins we believe that traditional protein analysis tools can be overly complex or inadequate and our goal is to make protein analysis simpler more quantitative and affordable our comprehensive portfolio of tools includes simple western systems that provide fresh insight into protein expression and biologics systems that probe the structure and purity of proteinbased therapeutics we have over  employees  systems installed around the world and our headquarters is in santa clara california for more information visit wwwproteinsimplecom contact tim harkness ceo proteinsimple   timharknessproteinsimplecom form  bruker corp for jun  filed by van ingen chris research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  bruker corp for jun  filed by van ingen chris by k wizard—  am et  httparchivefastedgarcomaezuoczbzrtzlqzzrz filed on june   more brkr news bruker introduces novel mass spectrometry solutions for maldi imaging metabolomics proteoform profiling and toxicology at asms  pr newswire   am et  bruker corporation to present at investor conferences pr newswire   am et  bruker introduces new solutions for microbial strain typing hospital hygiene and infection control at the asm microbe  meeting pr newswire   am et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top sbgi log in for events holx caty gmed aehr pbf log in for events ryi tier etm sons find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  brkr stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsbrkr bruker corporation    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all bruker announces date and time of second quarter  earnings release and webcast pr newswire –  pm et  billerica mass to listen to the webcast investors can go to httpirbrukercom and click on the bruker earnings release hyperlink to access the webcast investors can also listen to the earnings webcast via telephone by dialing  or  and referencing brukers second quarter  earnings conference call exwells fargo trader wins appeal in sec insider trading case reuters –  pm et  the us securities and exchange commission has affirmed the dismissal of an administrative case against a former wells fargo wfc  co trader after two commissioners split on whether the evidence proved he engaged in insider trading briefbruker says chris ingen inteds to retire from cos board reuters –  pm et  bruker corp brkr  bruker corp brkr  on june   chris van ingen informed co of his intention to retire from companys board of directors effective june   bruker corp brkr  ingens decision to retire was for medical reasons and not related to any disagreement with company bruker announces novel nmr phenomics research capabilities pr newswire –  am et  brisbane australia june    at the metabolomics society meeting  bruker brkr announces a new solution for the quantification of metabolites in urine using nuclear magnetic resonance urine metabolic analysis is particularly valuable and informationrich because the metabolic pathways of a wide range of nutrients drugs and environmental contaminants can be identified in urine even if  healthcare stock performance review  organovo cr bard bruker and dexcom pr newswire –  am et  new york june   if you want a stock review on onvo bcr brkr or dxcm then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister organovo  san diego california headquartered organovo holdings incs onvo stock finished thursdays session  higher at  with a total trading volume of  shares bruker introduces novel mass spectrometry solutions for maldi imaging metabolomics proteoform profiling and toxicology at asms  pr newswire –  am et  indianapolis june   bruker brkr is showcasing several new and innovative highperformance mass spectrometry solutions for metabolomics proteoform profiling and toxicology at asms  bruker corporation to present at investor conferences pr newswire –  am et  billerica mass jefferies  healthcare conference new york nythursday june   at  pm eastern timefrank laukien president and chief executive officerjuergen srega president bruker calid group bruker introduces new solutions for microbial strain typing hospital hygiene and infection control at the asm microbe  meeting pr newswire –  am et  new orleans june   at the american society for microbiology microbe  meeting bruker brkr introduces major innovations for strain typing hospital hygiene and infection control bruker launches the s tiger™ series  wdxrf system for elemental analysis in industrial and academic research and materials quality control pr newswire –  am et  karlsruhe germany may    today bruker brkr announces the launch of its new s tiger series  the nextgeneration wavelength dispersive xray fluorescence spectrometer briefbruker announces new  mln share repurchase program and qtrly dividend reuters –  am et  bruker corp brkr  bruker brkr announces new  million share repurchase program and quarterly dividend  sets quarterly cash dividend of per share  bruker brkr announces new  million share repurchase program and quarterly dividend  bruker corp brkr  intends to fund repurchases under this share repurchase program from cash on hand and available borrowings under its existing credit facility bruker announces new  million share repurchase program and quarterly dividend pr newswire –  am et  billerica mass under this program the company may repurchase its common stock from time to time in amounts at prices and at such times as the company deems appropriate subject to market conditions legal requirements and other considerations briefbruker acquires emerging light sheet microscopy company luxendo reuters –  am et  bruker corp brkr  financial details of transaction were not disclosed  financial details of transaction were not disclosed  bruker brkr acquires emerging light sheet microscopy company luxendo source text for eikon further company coverage bruker acquires emerging light sheet microscopy company luxendo pr newswire –  am et  billerica mass headquartered in heidelberg germany luxendo was founded in september  under the technical leadership of dr lars hufnagel group leader of the embl cell biology and biophysics unit luxendo was able to rapidly develop robust product solutions based on the patented spim technology how these medical laboratories  research stocks are faring  vwr corp bruker perkinelmer and charles river labs pr newswire –  am et  new york may   stockcallerscom has initiated research reports on these four stocks vwr corp vwr bruker corp brkr perkinelmer inc pki and charles river laboratories international inc crl companies in the medical laboratories and research industry are focused on performing various tests on patients that give them information on patients health httpstockcallerscomregistration bruker reports first quarter  financial results pr newswire –  pm et  billerica mass brukers brkr revenues for the first quarter of  were  million an increase of  compared to the first quarter of  first quarter  gaap earnings per diluted share were  compared to  in the first quarter of  bruker corporation to present at the nd annual deutsche bank health care conference pr newswire –  pm et  billerica mass a live audio webcast of the presentation will be available on the investor section of the companys web site at httpirbrukercom a replay of the presentation will be posted on the bruker corporation brkr website after the event and will be available for  days following the presentation page page  todays and upcoming events aug  brkr to announce q earnings after market confirmed aug  brkr earnings conference call at  pm listen past events last  days jun  brkr exdividend for  on  announce date  record date  pay date  may  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe margaret hamburg stephen ostroff  genomeweb skip to main content rss feeds twitter linkedin log in join now business  policybusiness news research funding policy  legislation regulatory news reimbursement technologymicroarrays  multiplexing pcr informatics sequencing mass spec sample prep gene silencinggene editing researchgenetic research gene expression research epigenetics research proteomics  protein research cell biology research diagnosticsmolecular diagnostics companion diagnostics biomarker discovery  validation drug discovery  development clinical sequencing clinical proteomics disease areascancer infectious disease cardiovascular disease neurological  psychological disease metabolic disease autoimmune disease inherited disease reproductive health applied markets resourceswebinars white papers the scan career blog job listings new products people in the news conferences  events main menu enter your keywords home » resources » people in the news » margaret hamburg stephen ostroff margaret hamburg stephen ostroff feb   after serving as us food and drug administration commissioner for nearly six years margaret hamburg is stepping step down from the post at the end of march stephen ostroff will serve as acting commissioner after hamburgs departure ostroff most recently served as the agencys chief scientist during her tenure hamburg has been a strong proponent of personalized medicine and the agency approved new molecularly targeted drugs for lung cancer breast cancer melanoma and cystic fibrosis the fda also issued critical guidelines to help industry advance drugs alongside companion diagnostics that identify patients most likely to benefit from treatment we have ushered in the era of personalized medicine across all of our medical product centers she said in a letter posted on the fdas website announcing her resignation a growing percentage of our recent approvals have involved targeted therapies offering many patients more effective response profiles andor reduced likelihood of side effects  the personalized medicine coalition recently estimated that  percent of the new drugs that the agency approved last year involved a biomarker and applauded her dedication to the field her commitment to personalized medicine was second to none pmc president edward abrahams said in a statement under hamburgs leadership the fda also released draft guidance on laboratorydeveloped tests last october although the move was highly controversial hamburg has stood by the agencys authority to regulate such tests and the need for added oversight as the practice of molecular medicine has grown rapidly it was under her leadership that the historic medical device user fee agreement iii was struck bringing significant new resources accountability and improvements to the device review process the diagnostic industry group advamed said in a statement in addition she was a key advocate to strengthen oversight for certain laboratorydeveloped tests which have become far more complex and critical to patient care and medical decision making  more like this jul   thomas loewald thomas loewald senior vice president and chief commercial officer at thermo fisher scientific since early  will resign from the company effective september  he joined the firms explosives detection business in  and held various positions over the years including senior vice president and president of laboratory products prior to that he was vice president of sales and marketing for tyco international jul   mark stevenson mark stevenson has been promoted to executive vice president and chief operation officer of thermo fisher scientific effective august  in his new role he will oversee operations of the companys laboratory products and analytical instruments businesses in addition to the life sciences solutions business since  when thermo fisher acquired life technologies stevenson has been executive vice president and president of life sciences solutions prior to that he was president and chief operating officer of life technologies and before that he was president and coo of applied biosystems jul   hans bishop hans bishop has been elected to agilents board of directors bishop is cofounder president and ceo of juno therapeutics a seattlebased biopharmaceutical company he has also held a range of executive positions in the pharmaceutical industry including as coo at dendreon president of specialty medicine at bayer healthcare and global commercial head for chiron jul   daniel sikkema quanterix has appointed daniel sikkema as vice president of acclerator services for the companys new simoa accelerator lab a dedicated environment for biomarker research custom assay development and clinical sample testing sikkema will work to expand the reach of quanterixs accelerator lab services in neurology oncology immunooncology infectious disease inflammatory diseases and other therapeutic areas he has previously worked at frontage lab bristolmyers squibb wyeth merck sanofi pasteur and glaxosmithkline jul   stephen pereira stephen pereira has been appointed to immunovias scientific advisory board pereira is a professor of hepatology and gastroenterology at university college london and is an honorary consultant in pancreaticobiliary medicine at ucl hospitals and the royal free hospital  jul   daniel macarthur the american society of human genetics has named daniel macarthur as the first recipient of its early career award he is an assistant professor in the analytic and translational genetics unit at massachusetts general hospital and harvard medical school and the codirector of the medical and population genetics program at the broad institute the new award which comes with  in prize money recognizes contributions of genetics and genomics scientists in the first  years of their careers as independent investigators macarthur and his colleagues developed the exome aggregation consortium exac database and website and its successor the genome aggregation database gnomad he also published many scientific articles on identifying genes associated with rare diseases in particular muscular disorders jul   mary thistle enterome has appointed mary thistle to its board of directors as a nonexecutive director thistle currently serves as chief operating officer at dimension therapeutics and has also served as senior vp of business development at cubist pharmaceuticals prior to joining dimension in  thistle held leadership positions at viacell in addition to developing therapeutic products for rare and metabolic liver diseases enterome also develops diagnostics to support therapies in microbiomerelated diseases such as inflammatory bowel disease and cancer jul   arthur beaudet the american society of human genetics has named arthur beaudet the recipient of this years victor a mckusick leadership award the award recognizes individuals whose professional achievements have fostered and enriched the development of human genetics as well as its assimilation into the broader context of science medicine and health beaudet who will receive the award along with a  prize at the ashg annual meeting in october is the henry and emma mayer professor in the department of molecular and human genetics and the department of pediatrics at baylor college of medicine he is a member of the national academy of medicine and the national academy of sciences and has received several other awards for his work beaudet has published more than  articles in the scientific literature  jul   kári stefánsson the american society of human genetics has named kári stefánsson the winner of this years william allan award a prize established in  that recognizes a scientist for substantial and farreaching scientific contributions to human genetics stefánsson is the founder of icelands decode genetics which has conducted a largescale population genetics research project in iceland he has published more than  articles in the scientific literature and has received several awards for his work including the european society of human genetics award in  jul   matthias raquet oneservice a swiss company offering complete managed service solutions consulting and learning for the life science diagnostics and medical device industries has appointed matthias raquet as ceo raquet joins oneservice from qiagen where he has worked since  most recently as vice president and head of global service solutions and global customer management prior to qiagen he worked in various management roles at amersham pharmacia jul   steven kanner caribou biosciences has appointed steven kanner as cso kanner has more than  years of experience in drug discovery and development he previously served in various research leadership roles at bristolmyers squibb astex pharmaceuticals and agensysastellas pharma most recently he served as vice president of discovery biology at arrowhead pharmaceuticals jul   chad brown nanostring technologies has appointed chad brown senior vice president of sales and marketing with more than  years of experience in life science tools and clinical diagnostics brown most recently served as the president and head of commercial operations for north america at qiagen prior to that brown was with roche diagnostics corporation where he held a series of commercial leadership positions in the applied sciences and centralized diagnostics businesses he has also held sales leadership positions in several medical device and healthcare companies including chiron diagnostics rotech healthcare apria healthcare and humanabrown succeeds barney saunders who is expected to stay with nanostring for a threemonth transition period before pursuing other professional opportunities jun   todd whitson karius has appointed todd whitson as chief commercial officer whitson joins karius from caredx where he served as cco prior to caredx he served as vp of commercial operations for ariosa diagnostics now part of roche and led sales at genzyme genetics later acquired by labcorp jun   ena cratsenburg will schroeder ginkgo bioworks has appointed ena cratsenburg as chief business officer and will schroeder as head of metabolic engineering cratsenburg joins ginkgo with over a decade of experience in business development in the biotech space she has held positions as senior vp of the consumer sector at intrexon senior vp of business development at evolva and vp of business development for amyris schroeder joins ginkgo from archer daniels midland adm where he served as cp of technology before adm schroeder spent  years at cargill overseeing strain and fermentations process development jun   chris van ingen chris van ingen a former member of brukers board of directors died on june  bruker said in a document filed with the us securities and exchange commission van ingen died less than a week after he told the firm that he would be retiring from the board due to medical reasons the cause of his death was not disclosed he had been on brukers board since  from  to  van ingen was with agilent technologies where he served as president of the firms bioanalytical measurement business breaking news startup spindiag raises €m in seed funding tempus rush university medical center collaborate to expand hospitals biobank sanger institute wins grant for antibiotic resistance surveillance new products posted to genomeweb this week thermo fisher agilent fluidigm and more streck names distributor in kuwait uw study examines prevalence of nonfounder brca brca other mutations in breast cancer the scan drive resistance gene drives might run into biological resistance the economist reports dalí dna collected forensic experts exhumed painter salvador dalís body to collect dna for a paternity test cbs news reports syntheticconservation biology disconnect yale environment  writes that synthetic and conservation biologists arent always on the same wavelength but they are trying to reach an understanding this week in science in science this week full crispr locus integration complex structure and more sponsorships about us advertise contact jobs subscribe privacy policy  copyright   genomeweb llc  all rights reserved van ingen chris top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active van ingen chris • palo alto ca how do i update this listing van ingen chris is based out of palo alto summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from van ingen chris enter your email address below and choose submit your email cancel contact info van ingen chris  page mill rd palo alto ca     recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free